Member Info for bewise

Chairman buying more...positive move :)

Imo, we should not be at this sp but here we are so for me a good time/ opportunity to average down before further test results...:)

:)

Good stuff :)...huge market for this

All good :)

The RNS and c call hopefully should give us a clear picture of the road ahead as we move closer towards P3. :)

Good news re the RNS ( investors conference ) It should steady the market and improve the sp.

The sp is beyond the company/board control. The selling is from nervous pi's. Vrp drops on small volume and rises on small volume. I do think a statement from the vrp board would be most welcome to clarify the RNS to the market. I am very assured that there has been no holdings RNS...A few directors buys would be most welcome also...

Howie, thank you for your point of view and your postings but I do think from what you have said you maybe need to do some research into the drug and the infrastructure surrounding it. The sp is in a dire state at this point of time and is out of sync completely with the RNS imo..

The weakness for vrp is not the drug as it clearly works and works extremely well or the results of the 3day tests....

You are barking up the wrong tree imo with dilution, dilution will not cut it... vrp need a partnership deal for P3 funding...

Thunderoad i agree with you..

The sp at this level is depressing to say the least for us shareholders and overblown but that's the market for you, the positive sign, the glimmer of light at this point is that there has been no holding RNS from II's. There is still massive value in the drug....some more positive news would be welcome...

Two interesting presentation downloads on the vrp site, one about are recent results and another from the JP Morgan conference early Jan. It will give you an idea of were we are at guys...

Complete over reaction by the market /PI's imo on the Rns, it was a small 3day trial but yet still reported unprecedented result with 1.5...the sp drop presents an opportunity to buy at these levels...going forward transformative news will be a partnership announcement for P3....lets watch this space and see what unfolds... :)

A good summary from the fierce biotech article today of the RNS...

The sell off is a over reaction and herd panic selling imo, the drug still works in copd, I would imagine once the panic subsides the sp will recover.

Still looking good :)...
Achieving additional bronchodilator response of this magnitude in COPD patients that have previously been considered to be maximally bronchodilated on background dual or triple therapy in a short, three-day study is clinically meaningful and unprecedented,

So 554 now has a name, good stuff as we head towards P3...news on the next set of results due anytime this month. :)

Things looking good guys

I believe things looking good guys as we move into 2019, the sp is oversold and presents a v good entry price imo...
http://www.veronapharma.com/blog/verona-pharma-appoints-kathleen-rickard-md-as-chief-medical-officer-to-lead-late-stage-clinical-development-of-rpl554/

Thumbs up and next trial results due in Jan 19! :) Things coming together nicely!